Clinical Trial Update: Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial assessing GM1 for prevention of oxaliplatin-induced neurotoxicity in stage II/III colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• GM1 (monosialotetrahexosyl ganglioside)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Yuhong Li | Conditions: Colorectal Cancer, Chemotherapy-induced Neutropenia | Phase 3 | Status: COMPLETED